During the study period, there was a positive effect size for new GP-recorded diagnoses of RhA (aHR 1·39, 95 % CI 1·12 - 1·74) and psoriasis (aHR 1·16, 95 % CI 1·10 - 1·23), when comparing the exposed cohort to the unexposed cohort, with both results being significant. Here, DHX9 is linked to psoriasis.